Drug Type Antibody drug conjugate (ADC) |
Synonyms |
Target |
Action inhibitors |
Mechanism CD74 inhibitors(HLA-DR antigens-associated invariant chain inhibitors), Mcl-1 inhibitors(Induced myeloid leukemia cell differentiation protein Mcl-1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Molecular FormulaC11H22N4O4 |
InChIKeyAGGWFDNPHKLBBV-YUMQZZPRSA-N |
CAS Registry159858-33-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Phase 2 | United States | 25 Feb 2025 | |
Acute Myeloid Leukemia | Phase 2 | Japan | 25 Feb 2025 | |
Acute Myeloid Leukemia | Phase 2 | Australia | 25 Feb 2025 | |
Acute Myeloid Leukemia | Phase 2 | Germany | 25 Feb 2025 | |
Acute Myeloid Leukemia | Phase 2 | Finland | 25 Feb 2025 | |
Acute Myeloid Leukemia | Phase 2 | France | 25 Feb 2025 | |
Chronic Myelomonocytic Leukemia | Phase 2 | Germany | 25 Feb 2025 | |
Chronic Myelomonocytic Leukemia | Phase 2 | Australia | 25 Feb 2025 | |
Chronic Myelomonocytic Leukemia | Phase 2 | France | 25 Feb 2025 | |
Chronic Myelomonocytic Leukemia | Phase 2 | Finland | 25 Feb 2025 |
Not Applicable | - | egypenaugq(jggaoxuevd) = significantly reduced in BAX/BAK or CD74 deficient cells, confirming a mitochondrial apoptosis mechanism specific to CD74 expressing cells rwtvfsctyg (yyhdxzgwpi ) View more | - | 09 Dec 2024 |